

# Roland Eid

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/7706386/roland-eid-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

20  
papers

255  
citations

7  
h-index

15  
g-index

27  
ext. papers

351  
ext. citations

3.6  
avg, IF

4.03  
L-index

#	Paper	IF	Citations
20	Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. <i>International Journal of Women's Health</i> , <b>2019</b> , 11, 431-437	2.8	61
19	New developments in the management of head and neck cancer - impact of pembrolizumab. <i>Therapeutics and Clinical Risk Management</i> , <b>2018</b> , 14, 295-303	2.9	44
18	The emerging use of immune checkpoint blockade in the adjuvant setting for solid tumors: a review. <i>Immunotherapy</i> , <b>2019</b> , 11, 1409-1422	3.8	17
17	Immunotherapy: last bullet in platinum refractory germ cell testicular cancer. <i>Future Oncology</i> , <b>2019</b> , 15, 533-541	3.6	12
16	ALK-rearranged adenocarcinoma transformed to small-cell lung cancer: a new entity with specific prognosis and treatment?. <i>Personalized Medicine</i> , <b>2018</b> , 15, 111-115	2.2	10
15	PARP inhibitors: a tsunami of indications in different malignancies. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 221-230.	0.6	7
14	Lung cancer and immunotherapy: a real-life experience from second line and beyond. <i>Future Oncology</i> , <b>2019</b> , 15, 3025-3032	3.6	6
13	HER2 in metastatic colorectal cancer: a new target to remember. <i>Biomarkers in Medicine</i> , <b>2021</b> , 15, 133-136	2.3	6
12	Prognostic and predictive biomarkers in nonmetastatic colorectal cancers. <i>Future Oncology</i> , <b>2018</b> , 14, 2097-2102	3.6	4
11	OSSMAR: An Observational Study to Describe the Use of Sunitinib in Real-Life Practice for the Treatment of Metastatic Renal Cell Carcinoma. <i>Journal of Global Oncology</i> , <b>2019</b> , 5, 1-10	2.6	3
10	The merit of tyrosine kinase inhibitors in the adjuvant setting of high-risk renal cell carcinoma: a meta-analysis. <i>Future Oncology</i> , <b>2018</b> , 14, 829-835	3.6	3
9	Bladder cancer knowledge in the Lebanese population: When ignorance could be harmful. <i>Bulletin Du Cancer</i> , <b>2018</b> , 105, 857-861	2.4	3
8	Awareness about the Human Papillomavirus (HPV) and HPV Vaccine Among Medical Students in Lebanon. <i>Journal of Medical Virology</i> , <b>2021</b> ,	19.7	3
7	Epidemiologic and histologic characteristics of CNS lesions: a 20-year experience of a tertiary center in Lebanon. <i>CNS Oncology</i> , <b>2020</b> , 9, CNS55	4	1
6	The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. <i>Immunotherapy</i> , <b>2021</b> ,	3.8	1
5	The Opinion of Oncologists on the Practice of Hypnosis among Cancer Patients in Lebanon. <i>Complementary Therapies in Medicine</i> , <b>2020</b> , 53, 102534	3.5	
4	Adjuvant tyrosine kinase inhibitors for renal cell carcinoma? No, thank you (at least for the present) reply. <i>Future Oncology</i> , <b>2018</b> , 14, 2225-2227	3.6	

- 3 Negativation of PD-L1 Postoperatively in Initially Inoperable Stage III Non-Small Cell Lung Cancer Treated with Pembrolizumab: Two Case Reports. *Case Reports in Oncology*, **2019**, 12, 421-425 1
- 2 Seizures in cancer patients: a vast spectrum of etiologies. *Future Neurology*, **2019**, 14, FNL30 1.5
- 1 In reply to: incorporating teleoncology practices in the undergraduate medical curriculum. *Future Oncology*, **2021**, 17, 11-12 3.6